Telomir Pharmaceuticals Reports Significant Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model

Telomir Pharmaceuticals (NASDAQ: TELO) has announced promising preclinical results for its lead candidate, Telomir-1, in treating Wilson’s disease, a rare genetic disorder characterized by excessive copper accumulation in the body. The data, derived from a genetic animal model, demonstrated Telomir-1's ability to significantly alleviate neurological, liver, and kidney symptoms associated with the disease. Notably, the treatment resulted in a 4- to 5-fold reduction in tremors, normalized movement behaviors, and a 50% decrease in liver copper levels in zebrafish models mimicking human pathology.

The implications of these findings are profound for the approximately 1 in 30,000 individuals worldwide affected by Wilson’s disease. Currently, treatment options are limited and primarily focus on managing symptoms rather than addressing the underlying cause. Telomir-1's mechanism of action, which involves regulating copper levels and improving organ histopathology, represents a potential paradigm shift in the therapeutic approach to this condition.

Telomir Pharmaceuticals is on track to file its first Investigational New Drug (IND) application by the end of the year, with human trials anticipated to commence in 2026. This development not only underscores the company's commitment to advancing longevity science but also highlights the broader potential of Telomir-1 in addressing age-related diseases by targeting telomere length. The success of Telomir-1 could pave the way for novel treatments in the field of genetic and degenerative diseases, offering a beacon of hope for patients and families affected by such conditions.